Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Exeltis","sponsor":"IntelGenx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intelgenx and Exeltis Healthcare S.L. Expand Rizaport\u00ae Commercialization Agreement to Include the European Union","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Exeltis","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin Signs Promotional Agreement with Exeltis on SOLOSEC\u00ae (secnidazole) Expanding Access for Adult Women Suffering with Bacterial Vaginosis and Adults with Trichomoniasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Exeltis","sponsor":"Luye Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Grants Exeltis Exclusive Commercialization Rights to its Innovative Alzheimer\u2019s Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Mexico and Poland","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Exeltis

    Menu

    Exeltis

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Exeltis

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Luye Pharma Grants Exeltis Exclusive Commercialization Rights to its Innovative Alzheimer’s Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Mexico and Polan...

              Details:

              Through the agreement, the company grants Exeltis exclusive rights to commercialize the Rivastigmine MD (rivastigmine), a multi-day transdermal patch for the treatment of Alzheimer’s disease.

              Lead Product(s): Rivastigmine

              Therapeutic Area: Neurology Product Name: Rivastigmine MD

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Luye Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement March 31, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Exeltis

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lupin Signs Promotional Agreement with Exeltis on SOLOSEC® (secnidazole) Expanding Access for Adult Women Suffering with Bacterial Vaginosis and Adults with Trichomoniasis

              Details:

              This partnership will expand the reach of SOLOSEC®, allowing more Healthcare Providers to be aware of the benefits of SOLOSEC®, and increase access for adult women suffering with bacterial vaginosis and adults with trichomoniasis.

              Lead Product(s): Secnidazole

              Therapeutic Area: Infections and Infectious Diseases Product Name: Solosec

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Lupin Ltd

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement January 27, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Exeltis

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Intelgenx and Exeltis Healthcare S.L. Expand Rizaport® Commercialization Agreement to Include the European Union

              Details:

              Under the terms of the current agreement, IntelGenx will grant Exeltis an exclusive license to manufacture and commercialize RIZAPORT® in the EU.

              Lead Product(s): Rizatriptan Benzoate

              Therapeutic Area: Neurology Product Name: Rizaport

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: IntelGenx

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement August 27, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY